HLHailong Li

Hailong Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hailong Li has a total of 92 co-authors. Here are the top co-authors by number of shared publications:

  • Rong Su

    Gansu University of Chinese Medicine

    8 shared publications
  • Meng Wang

    Department of Internal Medicine, First School of Clinical Medicine, Gansu University of Chinese Medicine, Lanzhou 730000, Gansu Province, PR China

    7 shared publications
  • Chunting Yang

    Gansu University of Chinese Medicine

    6 shared publications
  • Xiaqing Gao

    Gansu University of Chinese Medicine

    4 shared publications
  • Fan Zhang

    Department of Geriatrics Affiliated Hospital of Gansu University of Traditional Chinese Medicine Lanzhou China

    3 shared publications
  • Lihua Shao

    Departments of Geriatrics, Affiliated Hospital of Gansu University of Chinese Medicine, Lanzhou, People’s Republic of China

    3 shared publications

Latest Publications

  • Open Access

    Integrative Multi-Omics and Mendelian Randomization Identify Platelet Indices as Causal Mediators in Diabetic Retinopathy

    by Hailong Li, Puqi Chen, Yanyan Wan, Meiyan Chen, Weina Wang, Siya Xie, Jianhui Xiao, Bing Liu

    Background: Diabetic retinopathy (DR) is a leading cause of blindness, with platelet dysfunction increasingly implicated. However, establishing a causal role and underlying mechanisms remains challenging. Methods: We employed an integrated multi-omics approach. Bidirectional two-sample Mendelian randomization (MR) using large-scale GWAS data (FinnGen R9, n=351,387) assessed causality between platelet indices and DR. Transcriptomic datasets (GSE94019, GSE102485) identified platelet-related genes (PRGs) via WGCNA and differential expression. Diagnostic signatures were refined using machine learning (Boruta, RF, LASSO). Single-cell RNA sequencing (GSE248284) revealed platelet-immune crosstalk. MR analysis also investigated causal effects of PRG expression (eQTLGen, n=31,684) on platelet indices. Computational pharmacology leveraging traditional Chinese medicine databases identified potential therapeutic compounds. Results: Forward MR identified platelet distribution width (PDW, OR=40.59, p<0.001) and mean platelet volume (MPV, OR=40.86, p<0.001) as significant causal risk factors for DR. Reverse MR showed higher expression of FTL (OR=0.96) and ATP2B2 (OR=0.96) attenuated platelet activation, while THBD increased risk (OR=1.01). A three-gene diagnostic panel (ATP2B2, FTL, THBD) achieved perfect accuracy (AUC=1.0). Single-cell analysis revealed distinct platelet subpopulations and dynamic crosstalk with immune cells via TGF-β, PDGF, and CCL signaling. Molecular docking identified folic acid as a high-affinity modulator of ATP2B2 (binding energy: -8.3 kcal/mol). Conclusion: This study establishes a bidirectional causal link between platelet indices and DR, identifying FTL, ATP2B2, and THBD as key mediators. The diagnostic panel and folate therapy offer novel strategies, repositioning platelets as active drivers of DR pathogenesis.

  • Open Access

    Targeting FMO3 suppresses the malignant phenotype of colorectal cancer: evidence from bioinformatics to functional experiments

    by Rong Su, Cuncun Huang, Zhe Jing, Shuping Qiu, Lihua Shao, Tinghong Jiao, Hongwei Wang, Hailong Li

    Flavin-containing monooxygenase 3 (FMO3) is a key metabolic enzyme involved in endogenous metabolism; however, its role in colorectal cancer (CRC) remains poorly understood. This study aimed to investigate the expression pattern, biological function, and potential clinical relevance of FMO3 in CRC. Publicly available transcriptomic datasets were analyzed to assess FMO3 expression and its association with clinical characteristics. Immunohistochemistry and in vitro functional assays were performed to evaluate the effects of FMO3 on CRC cell proliferation, cell-cycle progression, migration, and invasion. Bioinformatics analyses were used to explore potential signaling pathways and immune-related associations. FMO3 was significantly upregulated in CRC tissues and cell lines and was associated with unfavorable clinicopathological features and poor prognosis. Silencing of FMO3 inhibited CRC cell proliferation by inducing G0/G1 cell-cycle arrest and suppressed migration and invasion by reversing epithelial-mesenchymal transition-related phenotypes. Mechanistically, FMO3 depletion attenuated PI3K/AKT signaling activity. In addition, FMO3 expression was correlated with immune cell infiltration patterns and immune checkpoint-related molecules. FMO3 promotes malignant progression of colorectal cancer and may serve as a potential biomarker and therapeutic target. Further in vivo and mechanistic studies are warranted to validate these findings.


  • Open Access

    Improvement of Risk Stratification for Diabetic Retinopathy Progression in Primary Care via an AI Model with Dynamic Anthropometric Data

    by Bing Liu, Jinchun Lin, Jianjun Zhang, Hailong Li

    Aim: To identify predictors of diabetic retinopathy (DR) progression on the basis of baseline data and annual dynamic changes and to develop an AI-driven personalized risk prediction model for improving clinical referrals. Methods: In this retrospective case‒control study, fundus images from 601 participants (273 progressors and 328 nonprogressors) were quantitatively analyzed via an AI system. The participants were categorized on the basis of second-year fundus changes. After random data splitting (70% training, 30% validation), LASSO and multivariate logistic regression were used for feature selection and model construction. Model performance was assessed by the area under the curve (AUC), calibration curves, and decision curve analysis (DCA). Results: The dominant risk factors were modifiable variables: elevated HbA1c (OR = 1.473, 95% CI: 1.249–1.739), increased BMI (OR = 1.457, 95% CI: 1.214–1.747) and increased waist circumference (OR = 1.083, 95% CI: 1.039–1.128). The model demonstrated robust and consistent discrimination, with AUCs of 0.799 (training) and 0.788 (validation). DCA showed clinical utility across a wide threshold probability range (0--0.85). Conclusions: Proactive management of modifiable risk factors is crucial. The developed AI-driven personalized prediction model shows robust performance and holds promise for enhancing referral precision in primary care, offering a practical strategy to improve DR management.

  • Open Access

    COPB2 drives gastric cancer progression via PI3K/AKT/NF-κB signaling: a multi-omics and functional study

    by Hailong Li, Dong Wei, Xiaqing Gao, Rong Su, Chunting Yang, Ping Tang, Xiqiu Yu, Yuhong Wu

    This study investigated the role of COPB2 in gastric cancer (GC) pathogenesis. Analysis of TCGA datasets and tissue microarrays revealed its upregulation in GC tissues compared to normal adjacent tissues, which was correlated with advanced tumor stage and lymphatic invasion and demonstrated significant diagnostic value (AUC = 0.895 and 0.851). Functional assays using lentiviral-mediated silencing in GC cells showed that COPB2 knockdown suppressed cell proliferation and migration, induced G0/G1-phase arrest, and promoted apoptosis. Mechanistic investigations through microarray, KEGG, and IPA analyses indicated that COPB2 dysregulation inactivated the PI3K/AKT and NF-κB signaling pathways. This led to the downregulation of key oncogenic effectors including Slug, FN1, CDH2, F2RL1, CDK6, CCND1, MMP9, CDKN2A, and SQSTM1, while upregulating tumor suppressors CDKN1B, CDKN1A, and DDIT3. In conclusion, COPB2 acts as an oncogene in GC, driving tumor progression through modulation of the cell cycle and key signaling pathways, highlighting its potential as a therapeutic target.


  • Open Access

    Dual oncogenic roles of TPD52 and TPD52L2 in gastric cancer progression via PI3K/AKT activation and immunosuppressive microenvironment remodeling

    by Hailong Li, Xiaqing Gao, Shuangming Guo, Shenfei Gao, Chunting Yang, Rong Su, Zhe Jing, Shuping Qiu, Ping Tang, Jing Han

    Aim: TPD52 (tumor protein D52) and TPD52L2 (tumor protein D52-like 2), members of the TPD52 gene family, have been implicated in multiple malignancies. However, their roles in gastric cancer (GC) remain elusive. Herein, we integrated multiomics analyses and experimental validation to elucidate their prognostic and functional significance in GC. Methods: Utilizing The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and tissue microarray datasets, we analyzed TPD52/TPD52L2 expression patterns in patients with GC. Survival analysis, Cox regression, and nomogram construction were performed to assess prognostic value. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes functional enrichment analysis and immune infiltration evaluation (Cell-type Identification By Estimating Relative Subsets Of RNA Transcripts‌/Estimation of STromal and Immune cells in MAlignant Tumour tissues using Expression data) (CIBERSORTx/ESTIMATE) were conducted to explore the molecular mechanisms involved. In vitro experiments (cell proliferation, migration, invasion, and apoptosis assays) were performed via lentivirus-mediated gene knockdown in gastric cancer cell lines AGS and MKN45 cells. Results: TPD52 and TPD52L2 were significantly overexpressed in GC tissues compared with their normal counterparts. Elevated TPD52L2 expression was significantly associated with advanced Tumor, Node, Metastasis (TNM) stage and independently predicted reduced overall survival according to multivariate Cox regression. Multivariate analysis identified TPD52L2 as an independent prognostic factor. Diagnostic Receiver Operating Characteristic (ROC) curves yielded area under the curve values of 0.813 (TPD52) and 0.807 (TPD52L2). The results of functional experiments suggested that TPD52/TPD52L2 knockdown inhibited proliferation, migration, G0/G1 arrest, and induced apoptosis. Mechanistically, TPD52/TPD52L2 silencing suppressed PI3K/Akt serine/threonine kinase (AKT)/mammalian target of rapamycin (mTOR) signaling and epithelial–mesenchymal transition marker expression. Conclusion: TPD52 and TPD52L2 are promising prognostic biomarkers in GC, with TPD52L2 exhibiting greater clinical relevance. Targeting these proteins may disrupt oncogenic signaling pathways and enhance immunotherapy efficacy, warranting further investigation in clinical trials.


  • Open Access

    Identification of Ferroptosis‐Related Hub Genes as Diagnosis Biomarkers and Therapeutic Monitoring for Major Depressive Disorder Diagnosis

    by Shenghui Huang, Shoupin Xie, Fei Feng, Yanyan Wan, Yanping Ma, Yafeng Wang, Fan Zhang, Xinhong Chen, Ping Tang, Hailong Li

    Major Depressive Disorder (MDD) is linked to increased neurodegenerative risk. Emerging evidence implicates ferroptosis in neuropsychiatric disorders, prompting investigation of its role in MDD through key gene identification. Three microarray datasets from the GEO database were analysed. Weighted gene co‐expression network analysis (WGCNA) identified MDD‐related module genes (MRGs) while ferroptosis‐related genes (FRGs) were extracted from the FerrDb database. Overlapping genes between MRGs and FRGs were prioritised for mechanistic exploration. Functional enrichment (GO/KEGG) and protein‐protein interaction (PPI) network analyses (via Cytoscape and CytoHubba) highlighted hub genes. Machine learning algorithms were applied to develop a diagnostic model, validated through nomogram analysis, calibration curves, decision curve analysis (DCA), ROC curves (AUC evaluation), gene set enrichment analysis (GSEA), and DGIdb‐based drug prediction. Differential expression analysis identified 1878 MDD‐associated genes (715 downregulated, 1163 upregulated). Four FRGs—MAPK14, WIPI1, DUSP1, and ULK1—emerged as diagnostic biomarkers, showing significant immune cell infiltration correlations (e.g., neutrophils, dendritic cells) and enrichment in pathways like MAPK signalling. The study highlights ferroptosis‐related genes (ULK1, MAPK14, WIPI1, DUSP1) as potential diagnostic and therapeutic targets in MDD, linked to neuroimmune interactions and cellular stress responses. These findings underscore MDD's pathophysiological complexity and may guide strategies for managing MDD and neurodegenerative comorbidities.


  • Open Access

    PGK1: A Common Biomarker and Therapeutic Target Linking Sarcopenia and Osteoporosis Through Fibroblast‐Mediated Pathways

    by Kun Zhang, Hailong Li, Xinhong Chen, Ping Tang, Meng Wang, Chunting Yang, Rong Su, Xiaqin Gao, Fan Zhang, Juan Han

    Sarcopenia and osteoporosis share pathophysiological links, but their co‐occurrence mechanisms remain unclear. This study aimed to identify molecular mediators of their co‐development using bioinformatics. Datasets for sarcopenia (GSE56815) and osteoporosis (GSE9103) were retrieved from GEO. Differentially expressed genes (DEGs) were analysed via edgeR and limma. Gene ontology (GO), Kyoto encyclopaedia of genes and genomes (KEGG) and weighted gene co‐expression network analysis (WGCNA) identified shared pathways and hub genes. Protein–protein interaction (PPI) networks were constructed using STRING and Cytoscape. We validated hub genes in independent datasets (GSE13850, GSE8479) and assessed via ROC curves. Immune infiltration, single‐cell analysis and drug prediction were performed. We identified 134 common DEGs (30 upregulated, 104 downregulated). WGCNA and PPI analysis revealed 14 hub genes (APOE, CDK2, PGK1, HRAS, RUNX2 etc.), all with ROC‐AUC > 0.6. PGK1 was consistently downregulated in both diseases and linked to 21 miRNAs and six transcription factors (HSF1, TP53, JUN etc.). Single‐cell analysis localised PGK1 predominantly in skeletal muscle fibroblasts. DrugBank identified lamivudine as a potential PGK1‐targeting therapeutic. PGK1 emerged as a central downregulated gene in sarcopenia and osteoporosis, enriched in fibroblasts and modulated by lamivudine. These findings highlight PGK1 as a shared diagnostic and therapeutic target, offering insights into musculoskeletal crosstalk.


  • Open Access

    Identification of HIBCH and MGME1 as Mitochondrial Dynamics‐Related Biomarkers in Alzheimer's Disease Via Integrated Bioinformatics Analysis

    by Hailong Li, Fei Feng, Shoupin Xie, Yanping Ma, Yafeng Wang, Fan Zhang, Hongyan Wu, Shenghui Huang

    Mitochondrial dynamics (MD) play a crucial role in the genesis of Alzheimer's disease (AD); however, the molecular mechanisms underlying MD dysregulation in AD remain unclear. This study aimed to identify critical molecules of MD that contribute to AD progression using GEO data and bioinformatics approaches. The GSE63061 dataset comparing AD patients with healthy controls was analysed, WGCNA was employed to identify co‐expression modules and differentially expressed genes (DEGs) and LASSO model was developed and verified using the DEGs to screen for potential biomarkers. A PPI network was built to predict upstream miRNAs, which were experimentally validated using luciferase reporter assays. A total of 3518 DEGs were identified (2209 upregulated, 1309 downregulated; |log 2 FC| > 1.5, adjusted p < 0.05). WGCNA revealed 160 MD‐related genes. LASSO regression selected HIBCH and MGME1 as novel biomarkers with significant downregulation in AD (fold change > 2, p < 0.001). KEGG enrichment analysis highlighted pathways associated with neurodegeneration. Luciferase assays confirmed direct binding of miR‐922 to the 3′UTR of MGME1. HIBCH and MGME1 are promising diagnostic biomarkers for AD with AUC values of 0.73 and 0.74. Mechanistically, miR‐922 was experimentally validated to directly bind MGME1 3′UTR.


  • Kaempferol inhibited invasion and metastasis of gastric cancer cells by targeting AKT/GSK3β pathway based on network pharmacology and molecular docking

    by Xia-Qing Gao, Hai-Long Li, Meng Wang, Chun-Ting Yang, Rong Su, Li-Hua Shao

    This study aims to explore the mechanisms of the inhibitory effect of kaempferol on the invasion and metastasis of gastric cancer (GC) cells through network pharmacology prediction and experimental verification. It identifies core targets via PPI network analysis and finds that kaempferol binds to these targets well. In vitro experiments showed that kaempferol could inhibit the proliferation, colony formation, migration and invasion of GC cells. Western blotting indicated kaempferol may reduce AKT and GSK3β phosphorylation, leading to lower expression of invasion-related genes SRC, MMP9, CXCR4, KDR, and MMP2. Overall, kaempferol may prevent migration and invasion of GC cells via the AKT/GSK3β signaling pathway.